Mylan’s decision to make a cheaper, generic EpiPen ‘baffles’ experts image

Business Insider, August 31, 2016
Lydia Ramsey, featuring blog post by Rachel E. Sachs (Academic Fellow alumna)


Read the full article

From the article:

"I and others who study these issues full time cannot understand why Mylan thought this would work to quell the widespread indignation over its pricing practices," Rachel Sachs, a law professor at Washington University in St. Louis, wrote in a Harvard Law blog post about how the company's decision "baffles" experts.

Among the issues Sachs raises with the authorized generic EpiPen is that pharmacists may not be able to substitute it, which would force people to buy the more expensive device. And, with the copay coupon in place for the branded version, it might make just as much sense to buy that one and pay roughly the same price. In the end, the generic version might not hurt Mylan's revenue from the device that much.

Read more here!

fda health law policy pharmaceuticals rachel sachs